Insulet price target lowered to $325 from $380 at RBC Capital

RBC Capital analyst Shagun Singh lowered the firm’s price target on Insulet (PODD) to $325 from $380 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 results for MedTech names. The firm notes that its intra-quarter due diligence suggests strong fundamentals and stable end markets, with no demand disruption in sight. RBC also believes that the current sentiment-driven dislocation is unwarranted, creating attractive opportunities across the landscape both into Q1 earnings season and longer-term. For the company, the firm notes that its HQ visits suggests that investor concerns around competition will prove to be overdone, though its key opinion leader checks suggest more limited upside in T2 patients due to GLP-1s than previously anticipated.